POM-V Prescription Required Companion Animal

Preglukord 5 mg Tablets for Dogs and Cats

Active ingredient: Prednisolone

Form

Tablet

Species

Cats Dogs

Manufacturer

Accord Healthcare B.V

VMD MA No.

42153/3002

What it's used for

Streptococci (including S. uberis). Escherichia coli (including β-lactamase producing strains). AN: 01491/2024 & 01490/2024

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Prednisolone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Preglukord 5 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Streptococci (including S. uberis).
Escherichia coli (including β-lactamase producing strains).
AN: 01491/2024 & 01490/2024

weight should be determined as accurately as possible.
The break line can be used to divide tablets into equal doses. Check the tablet - look
for a score line (a groove indicating where the tablet can be split).
Hold the tablet between your thumbs and forefingers with the scoreline towards you.
Apply gentle, even pressure along the score line until it splits the tablet in two.
Starting dose: 0.5 - 2.0 mg per kg bodyweight once per day.
Administration for one to three weeks at the above dosage levels may be required. For
longer term treatment: when after a period of daily dosing the desired effect has been
achieved, the dose should be reduced until the lowest effective dose is reached. The
reduction of the dose should be made by alternate day therapy and /or by halving the
dose with intervals of 5-7 days until the lowest effective
dose is reached.

Do not use in animals with:
- Viral, mycotic or parasitic infections that are not controlled with an appropriate
treatment
- Diabetes mellitus
- Hyperadrenocorticism
- Osteoporosis
- Heart failure
- Renal insufficiency
- Corneal ulceration
- Gastro-intestinal ulceration
- Glaucoma
Do not use in cases of hypersensitivity to the active substance, to other
corticosteroids, or to any of the excipients.
See also sections 3.7 and 3.8.

Target species: Dogs and Cats
Very common
(>1 animal / 10 animals treated):
Panting, Polyuria, polydipsia, polyphagia
, Elevated
triglyceride
, hypocortisolaemia
Common
(1 to 10 animals / 100 animals
treated):
Vomiting, Diarrhoea
Opportunistic infection, delayed healing
Uncommon*
(1 to 10 animals / 1 000 animals
treated):
Behavioural disorder (aggression, restlessness)Rare*
(1 to 10 animals / 10 000 animals
treated):
Hyperadrenocorticism (iatrogenic), Cushing’s
disease (iatrogenic), Diabetes mellitus
Hepatomegaly, elevated liver enzymes, elevated
serum alkaline phosphatase (ALP), eosinopenia,
lymphopenia, neutrophilia
Muscle wasting
Skin thinning, alopecia
Gastrointestinal ulceration
Very rare*
(<1 animal / 10 000 animals
treated, including isolated
reports):
Anaphylactic or hypersensitivity reactions,
Pancreatitis
Undetermined frequency (cannot
be estimated from available data)
Elevated parathyroid (PTH) concentration, low
thyroxine (T4), decreased lactate dehydrogenase
(LDH), decreased aspartate aminotransferase
(AST), hyperalbuminaemia, hypernatraemia,
hypokalaemia
Muscle weakness, osteoporosis, inhibition of
longitudinal growth of bones
Increased weight, water retention, redistribution of
body fat
Calcinosis cutis
After systemic administration and particularly during the early stages of therapy.
The significant increase in triglycerides noticed can be a part of possible iatrogenic
hyperadrenocorticism (Cushing’s disease) involving significant alteration of fat,
carbohydrate, protein and mineral metabolism.
The significant dose related cortisol suppression noticed during therapy is a result
of effective doses suppressing the hypothalamic-pituitary-adrenal-axis. Following
cessation of treatment, signs of adrenal insufficiency can arise and this may render
the animal unable to deal adequately with stressful situations.
Corticosteroid use may delay wound healing and the immunosuppressant actions
may weaken resistance to or exacerbate existing infections.
May be exacerbated by steroids in animals given non-steroidal anti-inflammatory
drugs and in animals with spinal cord trauma.
With long term use.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

Glucocorticoids can produce symptomatic improvements without treating the
underlying disease. Where appropriate, use of the product should be combined with
treatment of the underlying disease and/or management of the affected animal’s
environment.

Special precautions for safe use in the target species:
In cases where a bacterial infection is present the product should be used in
association with suitable antibacterial therapy. Pharmacologically-active dose levels
may result in adrenal insufficiency. This may become apparent particularly after
withdrawal of corticosteroid treatment. The treatment should not be suddenly
withdrawn. This effect may be minimised by institution of alternate-day therapy if
practical. The dosage should be reduced and withdrawn gradually to avoid
precipitation of adrenal insufficiency. Corticoids such as prednisolone, exacerbate
protein catabolism. Consequently, the product should be carefully administered in old
or malnourished animals. Corticoids such as prednisolone should be used with caution
in patients with hypertension, epilepsy, burns, previous steroid myopathy, in
immunocompromised animals and in young animals as corticosteroids may induce a
delayed growth. Treatment with the veterinary medicinal product may interfere with
vaccination efficacy. (See section 3.8)
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Prednisolone or other corticosteroids may cause hypersensitivity (allergic reactions).
People with known hypersensitivity to prednisolone or other corticosteroids, should
avoid contact with the veterinary medicinal product.
Prednisolone may lead to gastrointestinal effects (nausea, vomiting, diarrhoea),
headache, and/or hyperactivity if accidentally ingested, particularly in children.
To avoid accidental ingestion, particularly by a child, unused tablets and unused half-
tablets should be returned to the container.
In case of accidental ingestion, especially by a child, seek medical advice
immediately and show the package leaflet or the label to the physician.
Corticosteroids can cause foetal malformations. Pregnant women should avoid
contact with the veterinary medicinal product.
Immediately wash hands thoroughly after handling the tablets.
Special precautions for the protection of the environment:
Not applicable.

Phenytoin, barbiturates, ephedrine and rifampicin may accelerate the metabolic
clearance of corticosteroids resulting in decreased blood levels and reduced
physiological effect.
The concomitant use of this veterinary medicinal product with non-steroidal anti-
inflammatory drugs may exacerbate gastrointestinal tract ulceration.
Administration of prednisolone may induce hypokalaemia and hence increase the risk
of toxicity from cardiac glycosides. The risk of hypokalaemia may be increased if
prednisolone is administered together with potassium depleting diuretics.
Precautions need to be taken when combining use with insulin.
Treatment with the veterinary medicinal product may interfere with vaccination
efficacy. When vaccinating with attenuated live vaccines, a two week interval should
be observed before or after treatment. Do not use concomitantly with attenuated live
vaccines.

This product does not require any special temperature storage conditions. Store in
the original container in order to protect from light.

Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.